These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 9459159

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
    Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, Wilson P, Pacciarini MA, Kaye SB, Cassidy J.
    Cancer Res; 1995 May 15; 55(10):2090-6. PubMed ID: 7743508
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.
    Clin Cancer Res; 2002 Mar 15; 8(3):718-28. PubMed ID: 11895901
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
    Samantas E, Kalofonos H, Linardou H, Nicolaides C, Mylonakis N, Fountzilas G, Kosmidis P, Skarlos D.
    Ann Oncol; 2000 Nov 15; 11(11):1395-7. PubMed ID: 11142478
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M.
    Clin Cancer Res; 2000 Mar 15; 6(3):868-73. PubMed ID: 10741709
    [Abstract] [Full Text] [Related]

  • 7. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J, Bláha M, Kubeček O, Maláková J, Špaček J, Bezouška J, Krulichová IS, Filip S.
    Cancer Chemother Pharmacol; 2016 Feb 15; 77(2):429-37. PubMed ID: 26678853
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
    de Jong RS, Mulder NH, Uges DR, Sleijfer DT, Höppener FJ, Groen HJ, Willemse PH, van der Graaf WT, de Vries EG.
    Br J Cancer; 1999 Feb 15; 79(5-6):882-7. PubMed ID: 10070885
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ.
    Int J Clin Pharmacol Ther; 2013 Feb 15; 51(2):96-105. PubMed ID: 23127487
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J, Wagner H, Niederle N, Heider A, Koschel G, Hecker D, Hanske M.
    Semin Oncol; 1996 Dec 15; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [Abstract] [Full Text] [Related]

  • 11. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.
    Clin Cancer Res; 2002 Mar 15; 8(3):691-7. PubMed ID: 11895897
    [Abstract] [Full Text] [Related]

  • 12. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL, Zhang XR, Liu JW, Chen ZY, Lin YC, Wang YD, Chen Q, Nan KJ, Song SP, Han FC, Zhu YZ, Li LY, Zheng YH, Chu DT.
    Zhonghua Zhong Liu Za Zhi; 2006 Apr 15; 28(4):309-12. PubMed ID: 16875636
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
    Xu L, Wang W, Sheng YC, Zheng QS.
    J Clin Pharm Ther; 2010 Oct 15; 35(5):593-601. PubMed ID: 20831683
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Oct 15; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 15. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
    Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J.
    Int J Oncol; 2009 Jun 15; 34(6):1629-36. PubMed ID: 19424581
    [Abstract] [Full Text] [Related]

  • 16. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.
    Eur J Cancer; 2017 Nov 15; 86():240-247. PubMed ID: 29055839
    [Abstract] [Full Text] [Related]

  • 17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Nov 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.
    Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Müller M, Groen HJ, Smit EF, de Vries EG.
    Int J Cancer; 1997 Nov 04; 73(3):362-6. PubMed ID: 9359483
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
    Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN.
    Cancer Chemother Pharmacol; 2002 Jul 04; 50(1):6-8. PubMed ID: 12111105
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.
    Sørensen JB, Stenbygaard L, Drivsholm L, Dombernowsky P, Hansen HH.
    Cancer Chemother Pharmacol; 1993 Jul 04; 32(5):399-402. PubMed ID: 8393388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.